UNC2025, a MERTK small molecule inhibitor, is therapeutically effective alone and in combination with methotrexate in leukemia models

PURPOSE: MERTK tyrosine kinase is ectopically expressed in 30–50% of acute lymphoblastic leukemias (ALL) and over 80% of acute myeloid leukemias (AML) and is a potential therapeutic target. Here, we evaluated the utility of UNC2025, a MERTK tyrosine kinase inhibitor, for treatment of acute leukemia....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: DeRyckere, Deborah, Lee-Sherick, Alisa B., Huey, Madeline G., Hill, Amanda A., Tyner, Jeffrey W., Jacobsen, Kristen M., Page, Lauren S., Kirkpatrick, Gregory G., Eryildiz, Fatma, Montgomery, Stephanie A., Zhang, Weihe, Wang, Xiaodong, Frye, Stephen V., Earp, H. Shelton, Graham, Douglas K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5354980/
https://ncbi.nlm.nih.gov/pubmed/27649555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1330
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados